rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    TGTX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      TG Therapeutics: 3 Key Takeaways for Long-Term Investors
      Nov 15Yahoo FinanceTGTX
      The Zacks Analyst Blog Highlights TG Therapeutics, BioCryst, Insmed and Madrigal
      Nov 11Yahoo FinanceBCRXINSMTGTX
      TG Therapeutics (TGTX) Lifts Revenue Guidance As Investors Ask If The Stock Is Pricey

      TG Therapeutics (TGTX) just delivered third quarter 2026 results that combined robust revenue with much slimmer profits. The business also raised full year revenue guidance to about US$1b, which sharpened investor focus. The strong third quarter report and higher 2026 revenue outlook landed on a stock that has already been on a powerful run, with a 30 day share price return of 16.06% and a year to date share price gain of 119.47% at a recent US$64.26. The 3 year total shareholder return of...

      Nov 11Yahoo FinanceTGTX
      TG Therapeutics (TGTX) Stock Stays Hard To Justify Despite Raised Revenue Guidance
      Nov 11Yahoo FinanceTGTX
      Is Earnings Beat Altering The Investment Case For TG Therapeutics (TGTX)?
      Nov 10Yahoo FinanceTGTX
      Did You Read My Latest On Biotech? TG Therapeutics Is Breaking Out! (NASDAQ:TGTX)

      Check out my latest article. I specified that I had call options on TG Therapeutics (TGTX)Check out this chart showing how stock valuation has been...

      Nov 10Seeking AlphaTGTX
      How Stock Of The Day TG Therapeutics Is Making Waves For Its Rivals

      Shares raced through a buy zone but are range of an alternate entry.

      Nov 10Investor's Business DailyTGTXNVS
      TG Therapeutics stock hits 52-week high at 63.68 USD
      Nov 10Investing.comTGTX
      TG Therapeutics, Inc. Q3 2026 Earnings Call Summary
      Nov 10Yahoo FinanceTGTX
      TG Therapeutics (TGTX) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Nov 10The Globe and MailTGTX
      What TG Therapeutics (TGTX) Said on Its Q3 Earnings Call
      Nov 9Yahoo FinanceTGTX
      TG Therapeutics Q3 2026 Earnings Call Transcript
      Nov 9BenzingaTGTX
      TG Therapeutics (TGTX) Reports Q3 Earnings: What Key Metrics Have to Say
      Nov 9Yahoo FinanceTGTX
      TG Therapeutics’ CEO Sees Global Revenue Exceeding $1B In 2026 – BRIUMVI Drives Q3 Topline Beat
      Nov 9Yahoo FinanceTGTX
      TG Therapeutics (TGTX) Beats Q3 Earnings and Revenue Estimates
      Nov 9Yahoo FinanceTGTX
      TG Therapeutics: Q3 Earnings Snapshot

      (TGTX) on Monday reported third-quarter earnings of $55.On a per-share basis, the Morrisville, North Carolina-based company said it had net income of 35 cents.

      Nov 9Yahoo FinanceTGTX
      TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance
      Nov 9Yahoo FinanceTGTX
      TG Therapeutics faces earnings test after profit disappointment
      Nov 9Investing.comTGTX
      TG Therapeutics (TGTX) Reports Initial Phase 1 Azer Cel Data In Progressive MS
      Nov 6Yahoo FinanceTGTX
      TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update
      Nov 2Yahoo FinanceTGTX
      EBay Leads 5 Stocks Near Buy Points, Shaking Off Market Retreat

      Ebay, Quest Diagnostics, Fastenal, Chubb are around buy points after earnings.

      Oct 31Investor's Business DailyEBAYTGTXDGX
      TG Therapeutics Is Up 98%, But The Story Isn't Finished
      Oct 30Yahoo FinanceTGTX
      Why TG Therapeutics (TGTX) Shares Climbed After Its Latest Update
      Oct 28Yahoo FinanceTGTX
      Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN), IQVIA Holdings (IQV) and TG Therapeutics (TGTX)

      Detailed price information for Iqvia Holdings Inc (IQV-N) from The Globe and Mail including charting and trades.

      Oct 28The Globe and MailTGTXELANIQV
      TG Therapeutics (TGTX) Stock May Be Underpriced Relative To Earnings
      Oct 27Yahoo FinanceTGTX
      How Investors Are Reacting To TG Therapeutics (TGTX) Early MS Cell Therapy Data
      Oct 27Yahoo FinanceTGTX
      TG Therapeutics: The Business Is More Attractive Than The Valuation (NASDAQ:TGTX)
      Oct 27Seeking AlphaTGTX
      TG Therapeutics (TGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
      Oct 26Yahoo FinanceTGTX
      TGTX Stock Rises 60% in 6 Months: Here's What You Should Know

      Detailed price information for Werewolf Therapeutics Inc (HOWL-Q) from The Globe and Mail including charting and trades.

      Oct 13The Globe and MailHOWLTGTX
      How TG’s MS Data Wave At MSToronto2026 At TG Therapeutics (TGTX) Has Changed Its Investment Story

      TG Therapeutics, Inc. has scheduled multiple data presentations at the 10th Joint ACTRIMS-ECTRIMS Meeting (MSToronto2026), including a late-breaking oral session on initial Phase 1 results for azer-cel, an allogeneic CD19-directed CAR T-cell therapy in primary progressive multiple sclerosis, alongside extensive new clinical and real-world analyses of BRIUMVI across relapsing multiple sclerosis and other autoimmune settings. This concentrated release of early azer-cel findings and long-term...

      Oct 9Yahoo FinanceTGTX
      TG Therapeutics (TGTX) Just Sparked A Bigger Question
      Oct 8Yahoo FinanceTGTX
      TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026
      Oct 8Yahoo FinanceTGTX
      Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm
      Sep 28MorningstarTGTX
      TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share

      TG Therapeutics (NASDAQ:TGTX) Chairman, President and Chief Executive Officer Mike Weiss said the company’s multiple sclerosis therapy, BRIUMVI, has captured more than one-third of the intravenous anti-CD20 market and continues to gain share as it approaches its fourth full year on the market. Spea

      Sep 18Yahoo FinanceTGTX
      TG Therapeutics (TGTX) Could Be 19% Undervalued After Its Recent Rebound

      TG Therapeutics (TGTX) steps into the spotlight ahead of its H.C. Wainwright conference appearance on September 14, drawing fresh attention after the stock recently bounced off its 50-day moving average. Across the past few months, TG Therapeutics has leaned into stronger momentum, with a 30-day share price return of 12.36% and a year-to-date share price return of 92.86%. The one-year total shareholder return of 73.17% and roughly 5x three-year total shareholder return suggest earlier buyers...

      Sep 18Yahoo FinanceTGTX
      TG Therapeutics Just Pulled A Bullish Move

      TG Therapeutics stock showed technical strength Wednesday, bounding off its 50-day moving average and nearing a breakout on the weekly chart.

      Sep 16Investor's Business DailyTGTX
      Insider Decision: Laurence N Charney Offloads $274K Worth Of TG Therapeutics Stock
      Sep 15BenzingaTGTX
      TG Therapeutics at H.C. Wainwright: BRIUMVI gains momentum
      Sep 14Investing.comTGTX
      TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
      Sep 10Yahoo FinanceTGTX
      TG Therapeutics at Cantor conference: briumvi gains momentum
      Sep 9Investing.comTGTX
      TG Therapeutics to Participate in the Cantor Global Healthcare Conference

      Fireside chat scheduled for Wednesday, September 9, 2026, at 11:30am ETNEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Cantor Global Healthcare Conference, being held on September 9 - 11, 2026. The fireside chat is scheduled to take place on Wednesday, September 9, 2026, at 11:30am ET. A live webcast of the fireside chat will be available on the Eve

      Sep 3Yahoo FinanceTGTX
      B. Riley Securities Remains a Buy on TG Therapeutics (TGTX)

      Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.

      Sep 3The Globe and MailTGTX
      TG Therapeutics, Stock Of The Day, Showing Bullish Signs

      The multiple sclerosis biotech has topped an early entry and is near a breakout.

      Sep 2Investor's Business DailyTGTX
      TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?
      Sep 2Yahoo FinanceTGTX
      Exclusive BAC Article: TG Therapeutics; Phase 3 SC BRIUMVI Data End 2026/Early 2027, Azer-Cel PMS Results 2nd Half 2026, Loading Dose Label Expansion IV BRIUMVI, And Catalysts (NASDAQ:TGTX)
      Aug 27Seeking AlphaTGTX
      TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade) (NASDAQ:TGTX)
      Aug 26Seeking AlphaTGTX
      TGTX Stock Outperforms 95% of Stocks. Here's Why.

      TGTX stock is recovering from an earnings sell-off in early August. building a base. The biotech stock is testing a key moving average.

      Aug 24Investor's Business DailyTGTX
      TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors (NASDAQ:TGTX)
      Aug 22Seeking AlphaTGTX
      TGTX Stock Alert: What to Know as Takeover Rumors Swirl Around TG Therapeutics

      TG Therapeutics stock rips higher on takeover speculation. But should you chase the momentum on Friday? Let’s find out!

      Aug 21BarchartTGTX
      Why is TG Therapeutics stock rallying today?
      Aug 21Investing.comTGTX

      This is the newest page. Registered accounts read further back.